EXTRIP II Conference, November 20-22 2019, Montreal, Canada
- Apr 14, 2019
- 1 min read
Updated: Oct 14, 2021
Toxins reviewed: Baclofen, Ethylene glycol, Methotrexate, Isoniazid, Calcium Channel Blockers, Beta-adrenergic antagonists, Dabigatran, Gabapentin/Pregabalin, Quinine/Chloroquine, Amatoxins
I keep coming back to posts like this because they're genuinely useful rather than filler. The point about staying consistent over chasing quick wins is one more people need to hear. If this was useful, there's a decent chance you'll get something out of https://connectioncafe.com/pgs/1inch_listing_uncx_as_a_scam_token_check_tool_is_a_strong_reputation_signal_for_liquidity_locking.html too.
You clearly know the subject, and it shows in how confidently this is all explained. It lines up with what I've seen work, and it challenged one assumption I'd been holding. There's a complementary piece I wrote about this at portalbridges that adds a bit more context.
This came at a good time for me, and your perspective gave me a few things to reconsider. You framed the trade-offs honestly, which is something plenty of posts conveniently skip. I shared a few of my own takeaways on this at kodiak-finance.com as well, in case it's relevant.